Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA
For more information, visit www.pierre-fabre.com, @PierreFabreGroup. For more information, visit www.pierre-fabre.com , @PierreFabreGroup . Pierre Fabre Laboratories Media Contact: Laurence Marchal, [email protected] PDF -https://mma.prnewswire.com/media/2416807/Pierre_Fabre_PDF.pdfLogo -https://mma.prnewswire.com/media/2416854/Pierre_Fabre_Laboratories.jpg View original content to download multimedia:...
France,
(informazione.it - comunicati stampa - salute e benessere)
![Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA]()
For more information, visit www.pierre-fabre.com, @PierreFabreGroup.
Pierre Fabre Laboratories Media Contact:
Laurence Marchal, [email protected]
PDF -
https://mma.prnewswire.com/media/2416807/Pierre_Fabre_PDF.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/pierre-fabre-laboratories-announces-the-submission-by-atara-biotherapeutics-of-tabelecleucel-tab-cel-biologics-license-application-for-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-with-u-302149982.html
 Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA)
Ufficio Stampa
